



# Singapore Society for Microbiology and Biotechnology Seminar: **MICA *Legionella* - Fast and accurate *L. pneumophila* enumeration**

Proudly presents:



**Dr. Sam Dukan**  
Founder, Diamidex  
PhD in Microbiology



**You are all welcome !**

Please register here:

Link: [REGISTRATION](#)

Date: Friday 30 Sept 2022

Time: 3pm (Singapore time)

### More about Diamidex :

- Diamidex, a young innovative company focused on rapid microbial detection and enumeration, have developed, MICA the very first **micro colony semi-automated counter solution** on the market. Thanks to its unrivalled **optical resolution** combined with a cutting-edge **software** using artificial intelligence, and some proprietary labeling, it can detect and count targeted culturable microorganisms at their early stage of micro colony in **record time**. With MICA *Legionella*, it is now possible to detect and enumerate culturable *Legionella pneumophila* after just 48 hours of incubation on GVPC plate (compared to 10 days with standard method). Such solution is now AOAC PTM certified. The certification demonstrates that MICA *Legionella* gives “equivalent or better results than ISO 11731:2017”. More solutions are available (*Pseudomonas aeruginosa* or *Alicyclobacillus* gaiacol positive) or will be available soon (coliform and bioburden).

### Biography of Dr. Sam Dukan :

- Trained at ENS Ulm, Sam holds a Magistère in Organic Chemistry and a PhD in Microbiology. He has been a Research Director at CNRS (Centre National de la Recherche Scientifique, France) for more than 20 years. Co-inventor of 12 patent families and co-author of more than 45 peer-reviewed scientific publications, Sam then co-founded 3 startups, Click4Tag, C4Hydro, C4 Biocontrol, which later merged to become Diamidex, a French company specializing in the rapid detection and enumeration of microorganisms of interest. Sam is also a co-founder of C4Diagnostics, a company active in the field of infectious disease diagnostics and TheraOnco, a company focused on ultra-targeted cancer therapies based on a click chemistry approach.